FULC - Fulcrum Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

FULC is currently covered by 10 analysts with an average price target of $9.36. This is a potential upside of $2.48 (36.05%) from yesterday's end of day stock price of $6.88.

Fulcrum Therapeutics's activity chart (see below) currently has 83 price targets and 82 ratings on display. The stock rating distribution of FULC is 48.28% HOLD, 44.83% BUY and 6.9% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 52.68% with an average time for these price targets to be met of 138 days.

Highest price target for FULC is $12, Lowest price target is $2, average price target is $7.9.

Most recent stock forecast was given by EDWARD TENTHOFF from PIPER SANDLER on 29-May-2025. First documented stock forecast 12-Aug-2019.

Currently out of the existing stock ratings of FULC, 14 are a HOLD (48.28%), 13 are a BUY (44.83%), 2 are a SELL (6.9%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$9

$2.12 (30.81%)

$15

2 days ago
(29-May-2025)

3/11 (27.27%)

$1.93 (27.30%)

170

Hold

$12

$5.12 (74.42%)

$4

8 days ago
(23-May-2025)

2/3 (66.67%)

$5.56 (86.34%)

184

Hold

$10

$3.12 (45.35%)

16 days ago
(15-May-2025)

0/3 (0%)

$3.4 (51.52%)

Hold

$4

$-2.88 (-41.86%)

$4

3 months 5 days ago
(26-Feb-2025)

11/18 (61.11%)

$0.68 (20.48%)

129

Hold

$4

$-2.88 (-41.86%)

$4

6 months 17 days ago
(14-Nov-2024)

2/3 (66.67%)

$0.68 (20.48%)

19

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is FULC (Fulcrum Therapeutics) average time for price targets to be met?

On average it took 138 days on average for the stock forecasts to be realized with a an average price target met ratio 52.68

Which analyst has the current highest performing score on FULC (Fulcrum Therapeutics) with a proven track record?

EDWARD TENTHOFF

Which analyst has the most public recommendations on FULC (Fulcrum Therapeutics)?

Edward Tenthoff works at PIPER SANDLER and has 5 price targets and 4 ratings on FULC

Which analyst is the currently most bullish on FULC (Fulcrum Therapeutics)?

Corinne Jenkins with highest potential upside - $8.12

Which analyst is the currently most reserved on FULC (Fulcrum Therapeutics)?

Tazeen Ahmad with lowest potential downside - -$4.88

Fulcrum Therapeutics in the News

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?